Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 13 14 15 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Luxendo–SEVERAL: investment, 201701 financing round Series A extension €2m bringing total to €8m co-led by LSP + EMBL Ventures + EMBLEM 2017-01-12
Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck 2017-01-12
Crescendo Biologics–Genedata: bioinformatics, 201701– license to Genedata Biologics as workflow platform for internal + partnered Humabody programs 2017-01-10
Amgen–Immatics: cancer immunotherapy, 201701– strategic collab $30m upfront + $500m milestones + royalties combining Xpresident + BiTE technologies 2017-01-09
Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m 2017-01-09
Epidarex Capital–Lilly: investment, 201701 existent one of several investors in Epidarex is Eli Lilly 2017-01-09
Eternygen–Berlin (govt): investment, 201701 financing round Series A totalling €8m incl co-investor VC Fonds Technologie managed by IBB 2017-01-09
Eternygen–Epidarex Capital: investment, 201701 financing round Series A totalling €8m incl lead investor Epidarex Capital 2017-01-09
Eternygen–Evotec: investment, 201701 financing round Series A totalling €8m incl co-investor Evotec AG 2017-01-09
Eternygen–MC Services: public relations, 201701 service existent by MC Services AG 2017-01-09
Eternygen–SEVERAL: investment, 201701 financing round Series A €8m led by Epidarex Capital plus Evotec + VC Fonds Technologie + 2 family offices et al 2017-01-09
Merck (DE)–Univ Texas: oncology, 201701–201912 strategic collab using MD Anderson’s APOLLO platform for cancer drug development 2017-01-09
OmicSoft–Qiagen: investment, 201701 acquisition €na of OmicSoft by Qiagen 2017-01-09
Servier–McDermott Will & Emery: legal services, 201701 advisor immuno-oncology co-developm agreem of Servier with Pieris Pharmaceuticals 2017-01-09
Anokion–Celgene: investment, 201701 acquisition of equity interest by Celgene as part of research collab research plus excl option to acquire Anokion 2017-01-08
Celgene–Anokion: immune tolerance inducing drugs, 201701– collab research $45m upfront + $10m milestones + equity share + right to acquire Anokion 2017-01-08
HepaRegenix–Boehringer: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–Germany (govt): investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–High-Tech Gründerfonds: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–MC Services: public relations, 201701 service existent by MC Services AG 2017-01-05
HepaRegenix–Novo Group: investment, 201701 financing round Series A totalling €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
HepaRegenix–SEVERAL: investment, 201701 financing round Series A €9m co-led by BIVF + Novo Seeds + incl HTGF + Coparion 2017-01-05
Merck (US)–Valneva: cell line, 201701– research license €na for development of new vaccines using EB66 technology to MSD Animal Health 2017-01-05
Servier–Pieris: cancer immunotherapy, 201701– collab €30m upfront + milestones to develop bi-specific ABs using Anticalin technology incl PRS-322 2017-01-05
Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners 2017-01-05
Affimed–Univ Texas: cancer immunotherapy, 201701– collab clinical + commerc to evalaute TandAbs with natural killer cell product of MD Anderson 2017-01-04
Aptarion Biotech–Noxxon: investment, 201701 Noxxon receives Aptarion shares as part of transfer of preclinical assets to Aptarion 2017-01-04
Aptarion Biotech–Noxxon: Spiegelmer technology, 201701 acquisition techn + preclinical assets + lab assets from Noxxon for cash + royalties + shares 2017-01-04
BioControl Systems–Merck (DE): investment, 201701 acquisition €na of BioControl Systems Inc by Merck KGaA 2017-01-04
InVivo Biotech Services–Bruker Corp: investment, 201701 acquisition €na of InVivo Biotech Services GmbH by Bruker 2017-01-04
SCiLS GmbH–Bruker Corp: investment, 201701 acquisition €na of SCiLS GmbH by Bruker 2017-01-04
Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 2017-01-04
Laboratoire LCA (MA)–SGS: investment, 201701 acqisition by SGS 2017-01-03
Bio-ITech–Eppendorf: investment, 2017Q1 acquisition of majority share in Bio-ITech BV by Eppendorf 2017-01-01
Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund 2017-01-01
dKK GmbH–Bavaria (govt): science/business park services, 201704– supply serivce dKK GmbH Martinried is new tenant at IZB Martinsried 2017-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 201701– license ww non-excl expansion 2017-01-01
Immunic–Bavaria (govt): science/business park services, 201701– supply service Immunic AG is new tenant at IZB Martinsried 2017-01-01
Middle Peak Medical–Symetis: investment, before 2017 acquisition by Symetis SA 2017-01-01
Pionyr Immunotherapeutics–Minapharm: biopharma production, 2017– supply service cell line + process dev + production of therap antibody by ProBioGen 2017-01-01
Ridgeway Biologicals–Klocke: investment, 201701 acquisition of Ridgeway Biologicals by IDT Biologika 2017-01-01
SciMab–Bavaria (govt): science/business park services, 201701– supply serivce SciMab GmbH is new tenant at IZB Martinsried 2017-01-01
Genkyotex–Genticel: investment, 201612–201702 reverse merger with Genkyotex’ owners holding 80% of merged entity 2016-12-22
PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems) 2016-12-22
C.B.S. Scientific–Genetrix (ES): investment, 201612 acquisition $900k of C.B.S. Scientific Company for $540k cash + $360k in shares by Sygnis AG 2016-12-21
Laagrima (MA)–SGS: investment, 201612 acquisition by SGS 2016-12-21
Purdue Pharma–Celltrion: rituximab, 201612– acquisition distribution rights for UK+IE+DE+IT+Benelux for biosimilar Truxima by Mundipharma 2016-12-20
C-Labs (CH)–SGS: investment, 201612 acquisition of controlling stake by SGS 2016-12-19
Active Spectrum–Bruker Corp: investment, 201612 acquisition €na of Active Spectrum by Bruker 2016-12-16
Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED 2016-12-16
Bluebird Bio–Apceth: contract manufacturing, 201612– collab strategic European manufacturing of Lenti-D + LentiGlobin by Apceth Biopharma GmbH 2016-12-15
Kohlberg Kravis Roberts–Lonza: investment, 201612–201707 acquisition of Capsugel for $5.5b in cash from KKR by Lonza 2016-12-15
Noxxon–Merck (US): cancer immunotherapy, 201612– collab clinical research combi of Keytruda + NOX-A12 in metastatic colorectal + pancreatic cancer 2016-12-15
Univercells–Gates Foundation: grant, 201612 grant $12m to reduce costs of vaccines for developing countries in collab w Batavia + Natrix 2016-12-15
Acousia Therapeutics–SEVERAL: investment, 201612 financing round €2.5m led by BIVF + incl KfW + Axxam 2016-12-14
Amcure–SEVERAL: investment, 201612 financing round Series B €6m led by LBBW Venture Capital GmbH 2016-12-14
Gilupi–Viroad: investment, 201612 acquisition of remaining shares in Gilupi by Viroad after becoming largest shareholder in 2012 2016-12-14
Carpegen–Lifescience Business Consulting: business consulting, 201612 supply portfolio/market analysis for sale of Gyronimo RT-PCR platform to Curetis 2016-12-13
Carpegen–Osborne Clarke: legal services, 201612 supply legal advisor for sale of Carpegen’s Gyronimo RT-PCR platform to Curetis 2016-12-13
Carpegen–Systec Elektronik: real-time PCR technology, 201612 collab existent development of Gyronimo platform co-owned by Carpegen + Systec 2016-12-13
Curetis–Carpegen: real-time PCR technology, 201612 acquisition €5m cash + €2.5m+€9m milestones of Gyronimo platform from Carpegen + Systec 2016-12-13
Genome Diagnostics–Illumina: DNA sequencing, 201612– collab GenDx non-excl reseller of Illumina porudcts for HLA sequencing in several countries 2016-12-13
BlueRock Therapeutics–Bayer: investment, 201612– financing round Series A totalling of $225m committed by Bayer + Versant Ventures 2016-12-12
BlueRock Therapeutics–SEVERAL: investment, 201612– launches with financing round Series A $225m committed by Bayer + Versant Ventures 2016-12-12
BlueRock Therapeutics–Versant Ventures: investment, 201612– financing round Series A totalling of $225m committed by Bayer + Versant Ventures 2016-12-12
Curetis–EU (govt): credit, 201612– up to €25m (incl €10m immediately) growth capital loan from EBI to advance Unyvery platform 2016-12-12
EURE-CART project–EU (govt): grant, 201612c– Horizon 2020 grant €5.9m 4y for clinical research on CART T-cell immunotherapy 2016-12-12
MolMed–EU (govt): grant, 201612c– Horizon 2020 grant €2m for MolMed for 4y as coordinator of EURE-CART project 2016-12-12
Biopremier (PT)–SGS: investment, 201612 acquisition of 70% stake by SGS 2016-12-09
Forge Therapeutics–Evotec: drug discovery services, 201612– collab strategic alliance lead optimisation of LpxC inhibitors by Evotec 2016-12-09
Numares–Ruth Group: public relations, 201612 service existent US PR + IR by The Ruth Group 2016-12-08
TCR2 Therapeutics–F2 Ventures: investment, 201612 financing round Series A totalling $44.5m led by MPM Capital + F2 Ventures 2016-12-07
TCR2 Therapeutics–MPM Capital: investment, 201612 financing round Series A totalling $44.5m led by MPM Capital + F2 Ventures 2016-12-07
TCR2 Therapeutics–SEVERAL: investment, 201612 financing round Series A $44.5m led by MPM Capital + F2 Ventures 2016-12-07
Roche–Novimmune: therapeutic antibody, 201612– excl license option €na for all rights to NI-0101 for autoimmune diseases to Genentech 2016-12-06
Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab 2016-12-05
Bayer–FaunaPhotonics: digital farming technology, 201612– collab developm sensor technology for insect pest monitoring w Bayer CropScience 2016-12-05
JnJ–AstraZeneca: budenoside, 201612 acquisition $330m of ww rights excl US to Rhinocort Aqua by Cilag GmbH International 2016-12-05
International Phenome Centre Network–Bruker Corp: NMR technology, 201611– collab Bruker is key partner for NMR technologies + methods + SOPs 2016-12-02
International Phenome Centre Network–Imperial College London: phenomics, 201611– collab MRC-NIHR UK Phenome Centre is founding partner of IPCN 2016-12-02
International Phenome Centre Network–Murdoch Univ: phenomics, 201611– collab Separation Science + Metabolomics Lab is founding partner of IPCN 2016-12-02
Boehringer–Bruker Corp: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System in Biberach 2016-12-01
Celgene–Evotec: drug discovery services, 201612–202111 strategic RnD collab $45m upfront using iPSC platform for drugs neurodegenerative diseases 2016-12-01
Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene 2016-12-01
Roche–Bruker Corp: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech 2016-12-01
Valneva–France (govt): investment, 201612 existent Bpifrance is 2nd largest shareholder owning 9.6% 2016-12-01
Valneva–Grimaud: investment, 201612 existent Groupe Grimaud is largest shareholder owning 15.6% 2016-12-01
Valneva–MVM: investment, 201612 private placement €7.5m w 2.9m new shares at €2.6 to MVM plus acqu existing shares results in 7.5% MVM share 2016-12-01
Boehringer–ACD/Labs: cheminformatics, 201611– supply deployment of ACD/Spectrus platform by Boehringer in Europe + North America 2016-11-30
Evotec–Merck (DE): target discovery technology, 201611– collab agreements to combine Merck genome editing technologies w Evotec screening (LT) 2016-11-30
G7 Therapeutics–Sosei: investment, 201611– acquisition 100% for CHF12m in cash of G7 Therapeutics by Heptares 2016-11-30
Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy 2016-11-30
AudioCure Pharma–High-Tech Gründerfonds: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors 2016-11-29
AudioCure Pharma–MED-EL: investment, 201611 financing round totalling €9m from new investor MED-EL + HTGF + private investors 2016-11-29
AudioCure Pharma–SEVERAL: investment, 201611 financing round €9m from new investor MED-EL + existing investor HTGF + private investors 2016-11-29
GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services 2016-11-29
Jackson Laboratory–Agilent: grant, 201611– Thought Leader Award to Peter Robinson at Jackons Lab for Genomic Medicine for clinical genomics research 2016-11-28
Menarini–Chugai: cancer drug, 201611– license ww excl for class I PI3K inhibitor PA799 to Berlin-Chemie Menarini 2016-11-28
Themis Bioscience–SEVERAL: investment, 201611 financing round Series B €10m 2nd + final closing with additional €3m 2016-11-28
Merck (US)–Proteros: drug discovery services, 201611– collab €na upfront + research funding + $167m milestones + royalties r+d small mol cancer drug 2016-11-22
next pagenext page 1 2 3 ... 13 14 15 ... 54 55 56  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top